Home > 暂无记录 暂无记录 行业新闻

行业新闻


  • Eculizumab MA1020

    Eculizumab, a humanized anti-complement C5 monoclonal antibody for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome, blocks the terminal complement pathway required for serum bactericidal activity (SBA).

    More

  • alirocumab MA1008

    More

  • Alemtuzumab MA1007

    More

  • Adalimumab MA1006

    More

  • atezolizumab MA1009

    Atezolizumab (MPDL3280A), a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1, was approved for the treatment of platinum-resistant metastatic non-small cell lung cancer (NSCLC) and cisplatin-resistant bladder cancer.

    More
    • Current page8, Total Pages305, Total Record1522 First Prev 678910 Next Last Goto
More